OCUGEN OCGN 深 沪
等待开盘 09-06 09:30:00 美东时间
1.03
0.000
0.00%
华盛通- 最 高1.04
- 今 开1.02
- 成交量 105.43万股
- 最 低 1.01
- 昨 收 1.03
- 总市值 3.21亿
- 52周最高 1.29
- 市盈率 静 --
- 换手率 0.34%
- 52周最低 0.515
- 委 比 64.19%
- 总股本 3.12亿
- 历史最高 18.77
- 量 比 0.75
- 振 幅 2.91%
- 历史最低 0.17
- 每 手 1
- 风险率 0.49%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Ocugen Enters Subscription Agreement with Carisma Therapeutics
Ocugen ( ($OCGN) ) just unveiled an announcement. On August 29, 2025, Ocugen, I...
50分钟前
Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
Shares of Alphabet Inc. (NASDAQ:GOOGL) (NASDAQ:GOOG) rose sharply in pre-market...
09-03 17:23
Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025
Ocugen Inc., a biotech leader in gene therapies for blindness, announced that its CEO, Dr. Shankar Musunuri, will participate in fireside chats at the H.C. Wainwright Global Investment Conference and a panel at Biotech on Tap in Munich. The company’s executives will also hold one-on-one meetings to discuss their clinical strategies. The fireside chat will be webcast and archived for 90 days. Ocugen focuses on gene-agnostic modifier therapies for ...
09-02 11:02
Cassava Sciences GAAP EPS of -$0.92
Cassava Sciences press release (NASDAQ:SAVA): Q2 GAAP EPS of -$0.92. Cash and cash equivalents were $112.4 million, with no debt, as of June 30, 2025. This compares to cash and cash equivalents of $12...
08-14 19:41
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease
Ocugen, Inc. announced that the European Medicines Agency (EMA) has accepted a single U.S.-based clinical trial for the submission of a Marketing Authorization Application (MAA) for its OCU410ST therapy targeting Stargardt disease. The trial, a pivotal confirmatory Phase 2/3 study, involves 51 participants and assesses the impact of a one-time subretinal injection of OCU410ST on reducing atrophic lesion size and improving vision. The EMA's positi...
08-13 10:27
Ocugen Announces $20M Securities Purchase Agreement
An update from Ocugen ( ($OCGN) ) is now available. On August 8, 2025, Ocugen, ...
08-11 20:59
Ocugen Announces $20M Direct Offering Of 20M Shares And 20M Warrants At A Combined Price Of $1.00
Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it has entered into a securities purchase agreement with Janus
08-09 05:07
Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants
Ocugen, Inc. has entered into a securities purchase agreement with Janus Henderson Investors to sell 20 million shares of common stock and warrants for the same amount at $1.00 per share. The warrants have an exercise price of $1.50, are exercisable immediately, and expire in two years. The offering is expected to raise approximately $20 million initially, with a potential additional $30 million if warrants are fully exercised. The offering is se...
08-08 21:03
Ginkgo Bioworks files $500M mixed securities shelf
Ginkgo Bioworks (NYSE:DNA) filed a prospectus for the offer and sale of $500M mixed securities shelf. This preliminary prospectus is not an offer to sell these securities. Filing More on Ginkgo Bi...
08-08 05:59
